ArticleJHLT open2025
Successful use of human amniotic allograft membrane in the treatment of recalcitrant driveline infections.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Driveline infections represent a significant source of morbidity and mortality in left ventricular assist device (LVAD) patients. Driveline infection occur in up to 40% of cases and have recurrence rates up to 50%. Current literature fails to demonstrate specific interventions capable of reducing prevalence of recalcitrant driveline infections (including serial debridement, muscle flap coverage of the driveline, driveline relocation, and device exchange). Human cryopreserved decellularized amniotic membrane (HCDAM) has been effectively used in chronic non-healing infected diabetic ulcers and reconstructive orthopedic and ophthalmology surgery for its advantageous biological properties. With no univocal consensus treatment option, we firstly explored HCDAM application in recalcitrant driveline infection and we describe the successful outcome in a patient who failed previous management with serial debridement. By wrapping HCDAM around the driveline we were able to obtain a positive tissue response leading to infection resolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.